Latest news with #ChristianHenry
Yahoo
08-05-2025
- Business
- Yahoo
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street's revenue expectations , but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% above analysts' consensus estimates. Is now the time to buy PacBio? Find out in our full research report. Revenue: $37.15 million vs analyst estimates of $35.3 million (4.3% year-on-year decline, 5.2% beat) Adjusted EPS: -$0.15 vs analyst estimates of -$0.19 (20.5% beat) Operating Margin: -1,155%, down from -210% in the same quarter last year Market Capitalization: $339 million 'We are off to a solid start to the year, highlighted by a full quarter of shipments of the Vega platform, record consumables revenue and improved non-GAAP gross margin,' said Christian Henry, President and Chief Executive Officer. Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, PacBio's sales grew at a decent 11.1% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. PacBio's recent performance shows its demand has slowed as its annualized revenue growth of 6.6% over the last two years was below its five-year trend. This quarter, PacBio's revenue fell by 4.3% year on year to $37.15 million but beat Wall Street's estimates by 5.2%. Looking ahead, sell-side analysts expect revenue to grow 10.2% over the next 12 months, an improvement versus the last two years. This projection is noteworthy and implies its newer products and services will fuel better top-line performance. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. PacBio's high expenses have contributed to an average operating margin of negative 256% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. Analyzing the trend in its profitability, PacBio's operating margin decreased significantly over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 300 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. PacBio's operating margin was negative 1,155% this quarter. The company's consistent lack of profits raise a flag. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. PacBio's earnings losses deepened over the last five years as its EPS dropped 1.8% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, PacBio's low margin of safety could leave its stock price susceptible to large downswings. In Q1, PacBio reported EPS at negative $0.15, up from negative $0.26 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects PacBio to improve its earnings losses. Analysts forecast its full-year EPS of negative $0.70 will advance to negative $0.69. We were impressed by how significantly PacBio blew past analysts' revenue expectations this quarter. We were also glad its EPS outperformed Wall Street's estimates. Zooming out, we think this was a good print with some key areas of upside. Investors were likely hoping for more, and shares traded down 2.5% to $1.16 immediately following the results. So do we think PacBio is an attractive buy at the current price? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-05-2025
- Health
- Yahoo
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand
Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio's HiFi sequencing technology at population scale - an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration highlights Thailand's growing leadership in precision medicine and offers a potential model for countries seeking to modernize newborn screening with genome-wide approaches. 'Our shared goal is to establish a robust and scalable research model for genomic newborn screening that helps uncover the genetic basis of undiagnosed conditions from birth,' said Professor Vorasuk Shotelersuk from the Center of Excellence for Medical Genomics, Chulalongkorn University, Thailand. 'We are excited to work with PacBio to bring this vision closer to reality for families in Thailand.' Traditional newborn screening programs have relied on targeted panels that detect a limited subset of conditions based on specific molecular pathologies. Recent advances in genome sequencing now make it possible to take a broader, more comprehensive approach, starting at birth. PacBio's HiFi WGS leverages long-read technology to generate highly accurate, complete genomic data, including regions that are typically inaccessible to short-read methods. In addition to resolving structural variants and repeat expansions, HiFi WGS captures epigenomic information in parallel, giving researchers a multidimensional view of the genome. This level of detail opens the door to identifying a wider range of genetic variants, many of which are implicated in early-onset and rare diseases that previously went undetected. 'Every child deserves the best possible start to life, and that begins with giving families and clinicians access to comprehensive genomic information from the very beginning,' said Christian Henry, President and Chief Executive Officer of PacBio. 'This collaboration demonstrates how advanced sequencing technologies like HiFi can enable broader insights at birth. It's deeply aligned with our mission at PacBio to make high-quality genomic information accessible where it's needed most, and we're proud to support Chulalongkorn University and Thailand as they lead the way in laying the foundation for a new model of care.' This collaboration positions Thailand as a regional leader in population-scale genomics and reflects Asia Pacific's expanding influence in the global genomics landscape. With an established foundation in public health and translational research, Thailand is uniquely prepared to explore how whole genome sequencing can enhance national healthcare strategies, beginning with newborn screening. By applying PacBio's HiFi long-read sequencing to this early-stage initiative, researchers gain a more comprehensive view of the genome, enabling the detection of variants that are often missed by traditional methods. The ability to capture a wider spectrum of genetic risk at birth sets a new benchmark for the potential of early disease detection, while also contributing to broader goals in carrier screening and public health planning. For Thailand, this project strengthens its role in advancing precision medicine and lays critical groundwork for future data-sharing frameworks and cross-border research collaborations that can inform more equitable and effective genomic healthcare worldwide. About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. About Faculty of Medicine, Chulalongkorn University in Thailand Chulalongkorn University is the oldest national university in the Kingdom of Thailand. The university has been active in international research activities and is committed to creating knowledge and innovation to transform Thai society into a creative and sustainable future. As part of the university's mission is to contribute the knowledge gained to the sustainable development of the country and society, the Faculty of Medicine is also actively involved in sharing knowledge with society through collaboration between industry, government, and Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, the benefits or expected benefits of using, PacBio products or technologies, including in connection with Thailand's efforts to integrate PacBio products into newborn screening; establishing a research model that may uncover the genetic basis of undiagnosed conditions, improve outcomes, ease uncertainty or offer answers earlier, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks inherent in developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption 'Risk Factors.' These forward-looking statements, including PacBio's preliminary unaudited financial information and PacBio's financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. Contacts (PacBio) Investors: Todd Friedmanir@ Media:pr@ Contacts (Chulalongkorn University) Media:prmdcu@ in to access your portfolio
Yahoo
09-04-2025
- Business
- Yahoo
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million
MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results Preliminary Q1 2025 Q1 2024 Revenue $36.9 million $38.8 million Instrument revenue $10.8 million $19.0 million Consumable revenue $20.1 million $16.0 million Service and other revenue $6.0 million $3.8 million Revio systems 12 28 Vega systems 28 - Annualized Revio pull-through per system ~$236,000 ~$254,000 Cash, cash equivalents, and investments $343.1 million $561.9 million Our preliminary revenue for the first quarter met our expectations despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds affecting the industry. Vega system orders accelerated in the first quarter as compared to the fourth quarter of 2024 as the combination of system capability and its attractive price point enabled purchases from both new and existing customers. Preliminary consumable revenue reached a company record. Annualized Revio pull-through per system was approximately $236,000, in line with the company's expectations in the low to mid $200,000s range. In response to ongoing market uncertainty, PacBio is executing a plan to reduce both headcount across all functions and non-headcount related expenses to lower its annualized non-GAAP operating expense run-rate by $45 million to $50 million by year end in relation to its prior guidance of $270 million to $280 million. Following the reductions, PacBio aims to focus on its highest-impact long-read platform development initiatives. Commentary by Christian Henry, President and CEO of PacBio: 'We are pleased with our start to the year as revenue met our expectations and we achieved record levels of consumable revenue. The Vega launch is progressing well, attracting more customers to HiFi sequencing and is expanding our addressable applications. While the funding and general macroeconomic environment is having an impact on our ability to place more instruments, particularly Revio systems at academic customers, we are encouraged by the consistent Revio utilization and annualized consumable pull-through, which remain in line with our expectations.' 'We believe we are on pace to achieve the financial goals we set earlier this year. However, given the persistent uncertainty surrounding academic and NIH funding, along with the introduction of new tariffs, we are taking strategic steps to reduce spending and reinforce our plan to reach positive cash flow by the end of 2027.' 'As a result of the reductions, we plan to focus on three key priorities: Accelerating the adoption of HiFi sequencing, Investing in initiatives that are targeted to improve gross margin, and Advancing innovation in our long-read sequencing portfolio to enhance platform scalability and reduce costs.' 'We are also restructuring our commercial organization to streamline management and improve sales force efficiency, while maintaining our commitment to serving customers across all segments and product lines.' Guidance and Financial Outlook The company reiterates its previous financial guidance including: Full-year 2025 revenue to be $155 million to $170 million. Growth in Vega shipments offsetting a year-over-year decline in Revio system shipments with annualized pull-through per Revio system in the low to mid $200,000s range. 2025 non-GAAP gross margin to be between 35% and 40%. As a result of the expected cost savings associated with the operating expense reductions, the company now expects its 2025 non-GAAP operating expenses to be lower compared to its previous guidance of $270 million to $280 million and expects its ending cash and investments balance to be higher than previous guidance of approximately $260 million. The company expects to provide more details at its earnings call scheduled for May 8, 2025. The preliminary unaudited financial information set forth above is subject to revision and is anticipated to be finalized in May 2025. PacBio's financial results could differ materially from the preliminary estimates above, which are not a comprehensive statement of PacBio's financial results and are not necessarily indicative of the results to be expected as of or for the fiscal period ended March 31, 2025, or any future period. Accordingly, you should not place undue reliance on these preliminary estimates. Quarterly Conference Call Information PacBio will hold its quarterly conference call on Thursday, May 8, 2025, at 4:30 p.m. Eastern Time to discuss its first quarter 2025 financial results. The call will be webcast and may be accessed at PacBio's website at Date: Thursday, May 8, 2025, at 4:30 pm ET (1:30 pm PT) Listen live via internet or replay: Toll-free: 1-888-349-0136 International: 1-412-317-0459 If using the dial-in option, please dial into the call ten minutes prior to start time using the appropriate number above and ask to join the 'PacBio Q1 Earnings Call.' About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Statement regarding use of non-GAAP financial measures This press release refers to non-GAAP gross margins and operating expenses, which PacBio reports in addition to, and not as a substitute for, financial measures calculated in accordance with GAAP. Additional details on PacBio's definition of non-GAAP gross margins and operating expenses can be found in the tables accompanying our fourth quarter 2024 earnings press release dated February 13, 2025. PacBio is unable to reconcile the non-GAAP gross margins and operating expense numbers included in this press release because certain items that impact these measures are out of PacBio's control and/or cannot be reasonably predicted at this time. PacBio believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of PacBio's non-GAAP financial measures as tools for comparison. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to PacBio's preliminary unaudited financial information as of and for the period ended March 31, 2025; the availability or timing of PacBio's final financial results as of and for the period ended March 31, 2025; PacBio's expectations for future operating results, revenue and guidance; PacBio's cost-saving plans and initiatives as well as the expected financial impact and timing of these plans and initiatives; risks that the operating expense reductions may have an adverse impact on PacBio's business and results of operations; risks that charges associated with PacBio's operating expense reductions may be greater than anticipated; the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies; and anticipated demand for PacBio's products and technologies in future periods. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to lengthening sales cycles; risks related to PacBio's ability to successfully execute and realize the benefits of acquisitions; the estimated size and estimated growth for the markets for PacBio's products may be smaller than expected; risks related to reductions in government funding for research grants or contracts; the impact of U.S. export restrictions and tariffs on the shipment of PacBio products to and sourcing of materials from certain countries; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development and commercialization timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption 'Risk Factors.' These forward-looking statements, including PacBio's preliminary unaudited financial information and PacBio's financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. Contacts Investors and Media:Todd Friedman650.521.8450ir@ in to access your portfolio
Associated Press
05-03-2025
- Sport
- Associated Press
Henry has 23 as Eastern Michigan beats Ohio 83-79
ATHENS, Ohio (AP) — Christian Henry had 23 points in Eastern Michigan's 83-79 victory over Ohio on Tuesday night to clinch a berth in the 2025 Mid-American Conference Tournament. EMU is tied with Toledo for fifth — a game behind the Ohio and Kent State — in the conference standings with one game remaining in the regular season. Henry shot 8 of 12 from the field and 6 for 6 from the free-throw line for the Eagles (16-14, 9-8). Jalen Terry scored 15 points and added six rebounds. Da'Sean Nelson shot 5 of 13 from the field and 4 for 4 from the foul line to finish with 14 points. Jackson Paveletzke led the Bobcats (16-14, 10-7) in scoring, finishing with 20 points and five assists. Shereef Mitchell added 17 points and three steals for Ohio. AJ Clayton finished with 12 points, six rebounds and two blocks. Nelson put up eight points in the first half for Eastern Michigan, who went into halftime tied 38-38 with Ohio. Henry's 15-point second half helped Eastern Michigan close out the four-point victory.
USA Today
31-01-2025
- Sport
- USA Today
Eastern Michigan vs. Kent State men's basketball tickets still available for Tuesday, February 4
The Kent State Golden Flashes (13-7, 4-4 MAC) meet a fellow MAC opponent, the Eastern Michigan Eagles (10-10, 4-4 MAC), on Tuesday, February 4, 2025 at George Gervin GameAbove Center. The game will tip off at 6:30 PM ET and is available via ESPN+. Buy tickets for Eastern Michigan vs. Kent State Shop college basketball tickets at SeatGeek Shop college basketball tickets at StubHub Eastern Michigan vs. Kent State game information Date: Tuesday, February 4, 2025 Tuesday, February 4, 2025 Time: 6:30 PM ET 6:30 PM ET How to watch on TV: ESPN+ ESPN+ Location: Ypsilanti, Michigan Ypsilanti, Michigan Venue: George Gervin GameAbove Center George Gervin GameAbove Center Tickets: Buy tickets here Watch college basketball on ESPN+! Eastern Michigan leaders So far this season, Jalen Terry is putting up 15.1 points, 3.2 assists and 1.5 steals per contest. Offensively, Christian Henry averages 15.3 points and 3.6 assists per contest. Da'Sean Nelson posts 15.7 points, 5.4 rebounds and 2.3 assists per contest. Defensively, he averages 1.0 steal and 0.8 blocked shots. On a per-game basis, Jalin Billingsley posts 10.8 points, 4.4 rebounds and 1.1 assists. Defensively, he delivers 0.7 steals and 0.7 blocked shots. Arne Osojnik is posting 8.4 points, 0.8 assists and 3.4 rebounds per contest this season. Kent State leaders On the hardwood, VonCameron Davis is averaging 15.9 points, 2.4 assists and 4.0 rebounds per game. Cli'Ron Hornbeak is piling up 8.6 points, 0.3 assists and 6.4 rebounds per game. Jalen Sullinger is posting 12.2 points, 1.7 assists and 1.5 rebounds per contest this season. From an offensive standpoint, Cian Medley is putting up 6.6 points and 4.3 assists per game. So far this season, Marquis Barnett averages 6.9 points, 3.4 rebounds and 1.0 assists per contest. At the other end, he puts up 1.2 steals and 0.4 blocked shots. Eastern Michigan vs. Kent State stats breakdown The Eagles are making 46.3% of their shots from the field, 5.4% higher than the Golden Flashes allow to opponents (40.9%). Eastern Michigan is 8-7 against the spread and 9-7 overall when shooting better than 40.9% from the field. The Golden Flashes shoot 41.7% from the field, 5.6% lower than the Eagles allow. Kent State is 3-1 against the spread and 5-1 overall when shooting higher than 47.3% from the field. The Eagles collect 28.7 boards per game, 4.1 less than the Golden Flashes. The Golden Flashes are 153rd in rebounding in the nation, and the Eagles are 340th. The 74.3 points the Eagles average are 10.1 more than the Golden Flashes give up. The Golden Flashes average 70.0 points, 8.7 fewer than the Eagles give up. Shop college basketball tickets at SeatGeek Shop college basketball tickets at StubHub We occasionally recommend interesting products and services. If you make a purchase by clicking one of the links, we may earn an affiliate fee. FTW operates independently, though, and this doesn't influence our coverage.
